Literature & Media

Effects of a Novel EP4 Agonist on Bone Metabolism in vitro

Scientific posters

This study demonstrated that KMN-159, our novel EP4 receptor agonist, is able to enhance the osteoblastic differentiation of human MSCs in vitro, strongly suggesting that it may increase bone formation in vivo and therefore be a potential candidate for augmentation of bone mass and enhancing fracture repair.

Do you have a question or comment for the presenter? Let us know.

To cite this poster: Wei, S., Patel, C., Owen, T., et al. Effects of a novel EP4 agonist on bone metabolism in vitro. Poster presented at: ASBMR 2019 Annual Meeting; September 20-23, 2019; Orlando, FL.
Download Copy (PDF)
Effects of a Novel EP<sub>4</sub> Agonist on Bone Metabolism <em>in vitro</em>
Cayman ChemicalCayman ChemicalCayman Chemical

Receive Our News & Literature Directly to Your Inbox!

Log in or register to subscribe to our email list. You will receive emails packed with new products and content that match your research interests. We only email once a week and you can unsubscribe at any time.